This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2). [provided by RefSeq, Jul 2008].
Ricco, Cau, Marchand, Marty, Rodde-Dunet, Fender, Allemand, Corsini: "Stent-graft repair for thoracic aortic disease: results of an independent nationwide study in France from 1999 to 2001." in: The Journal of thoracic and cardiovascular surgery, Vol. 131, Issue 1, pp. 131-7, (2006) (PubMed).
Chiou, Wu, Chien, Cheng, Wong, Chen, Lin, Lee: "NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan." in: Cancer letters, Vol. 223, Issue 1, pp. 93-101, (2005) (PubMed).